176 related articles for article (PubMed ID: 37689596)
1. Dynamic contrast-enhanced MRI radiomics model predicts epidermal growth factor receptor amplification in glioblastoma, IDH-wildtype.
Sohn B; Park K; Ahn SS; Park YW; Choi SH; Kang SG; Kim SH; Chang JH; Lee SK
J Neurooncol; 2023 Sep; 164(2):341-351. PubMed ID: 37689596
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Prognosis in Glioblastoma Using Radiomics Features of Dynamic Contrast-Enhanced MRI.
Pak E; Choi KS; Choi SH; Park CK; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Sep; 22(9):1514-1524. PubMed ID: 34269536
[TBL] [Abstract][Full Text] [Related]
3. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
4. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
5. MRI Features May Predict Molecular Features of Glioblastoma in
Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
[TBL] [Abstract][Full Text] [Related]
6. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
7. Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant.
Sohn B; An C; Kim D; Ahn SS; Han K; Kim SH; Kang SG; Chang JH; Lee SK
J Neurooncol; 2021 Dec; 155(3):267-276. PubMed ID: 34648115
[TBL] [Abstract][Full Text] [Related]
8. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
Park YW; Kim S; Park CJ; Ahn SS; Han K; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2022 Dec; 32(12):8089-8098. PubMed ID: 35763095
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.
Park JE; Kim HS; Park SY; Nam SJ; Chun SM; Jo Y; Kim JH
Radiology; 2020 Feb; 294(2):388-397. PubMed ID: 31845844
[TBL] [Abstract][Full Text] [Related]
10. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
11. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas.
Pan T; Su CQ; Tang WT; Lin J; Lu SS; Hong XN
Acta Radiol; 2023 Sep; 64(9):2552-2560. PubMed ID: 37331987
[TBL] [Abstract][Full Text] [Related]
12. Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma.
Li ZC; Bai H; Sun Q; Zhao Y; Lv Y; Zhou J; Liang C; Chen Y; Liang D; Zheng H
Cancer Med; 2018 Dec; 7(12):5999-6009. PubMed ID: 30426720
[TBL] [Abstract][Full Text] [Related]
13. Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Li Z; Zhao W; He B; Koh TS; Li Y; Zeng Y; Zhang Z; Zhang J; Hou Z
Contrast Media Mol Imaging; 2020; 2020():8843084. PubMed ID: 33299387
[TBL] [Abstract][Full Text] [Related]
14. Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.
Park CJ; Choi YS; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
Neuroradiology; 2020 Mar; 62(3):319-326. PubMed ID: 31820065
[TBL] [Abstract][Full Text] [Related]
15. Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status.
Hu Y; Zhang N; Yu MH; Zhou XJ; Ge M; Shen DD; Hua Y; Shi JL; Jia ZZ
Eur J Radiol; 2020 Oct; 131():109247. PubMed ID: 32891974
[TBL] [Abstract][Full Text] [Related]
16. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
[TBL] [Abstract][Full Text] [Related]
17. Genetic Alterations of Epidermal Growth Factor Receptor in Glioblastoma: The Usefulness of Immunohistochemistry.
Lee M; Kang SY; Suh YL
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):589-598. PubMed ID: 29912767
[TBL] [Abstract][Full Text] [Related]
18. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
19. A radiomics model based on DCE-MRI and DWI may improve the prediction of estimating IDH1 mutation and angiogenesis in gliomas.
Wang J; Hu Y; Zhou X; Bao S; Chen Y; Ge M; Jia Z
Eur J Radiol; 2022 Feb; 147():110141. PubMed ID: 34995947
[TBL] [Abstract][Full Text] [Related]
20. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
